Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rigel Pharmaceuticals Inc RIGL

Healthcare Biotechnology
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the... see more

Recent & Breaking News (NDAQ:RIGL)

Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update

PR Newswire April 30, 2024

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PR Newswire April 10, 2024

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

PR Newswire April 4, 2024

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

PR Newswire March 12, 2024

Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

PR Newswire March 5, 2024

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update

PR Newswire February 27, 2024

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®

PR Newswire February 22, 2024

Rigel Pharmaceuticals Provides Business Update

PR Newswire January 8, 2024

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PR Newswire January 5, 2024

Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma

PR Newswire January 4, 2024

Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire January 3, 2024

Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers

PR Newswire December 8, 2023

Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update

PR Newswire November 7, 2023

Rigel to Present at the Jefferies London Healthcare Conference

PR Newswire November 6, 2023

Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition

PR Newswire November 2, 2023

Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update

PR Newswire October 31, 2023

Rigel Announces Presentation at the Upcoming IDWeek 2023

PR Newswire October 11, 2023

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PR Newswire October 6, 2023

Rigel to Present at the 2023 Cantor Global Healthcare Conference

PR Newswire September 20, 2023

Rigel to Participate in Upcoming September Investor Conferences

PR Newswire August 30, 2023